EUMETSAT
14.12.2022 10:45:38 CET | Business Wire | Press release
Tonight’s launch of a highly advanced meteorological satellite from, Kourou, French Guiana, heralds the start of a new era for weather forecasting in Europe, EUMETSAT Director-General Phil Evans said.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005463/en/
MTG-I1 is successfully launched on an Ariane-5 rocket from Kourou, French Guiana (Photo: EUMETSAT)
The satellite, MTG-I1, is the first of a new generation of meteorological satellites carrying more advanced and precise instruments for monitoring and forecasting severe weather events such as storms, lightning, fog and wildfires.
It was successfully launched on an Ariane-5 rocket at 21:30 CET and is on its way to its correct orbit, 36,000km above the Equator.
“MTG-I1 will generate images of Europe and Africa every 10 minutes, faster than has been possible up until now, and in higher resolution, more precise detail,” Evans said.
“This data will help meteorologists meet one of their main challenges – timely and accurate forecasts of rapidly developing severe weather events – so that citizens, first responders and civil authorities can take appropriate action.
“The satellite’s lightning imager will continuously map lightning flashes between clouds and from clouds to the ground, which is a first for Europe with significant community and aviation industry safety benefits.”
MTG-I1 – full name Meteosat Third Generation – Imager 1 – will undergo a 12-month commissioning phase, in which its instruments will be calibrated and the data they produce validated, before becoming operational.
It will be operated from EUMETSAT’s headquarters in Darmstadt, Germany.
“Meteosat Third Generation is a European success story,” Evans said. “No European nation could afford to develop and operate such a system on its own. By combining the resources of our 30 member states, including their scientific and technical expertise, we are able to bring about a new era in weather and climate monitoring.”
More information about MTG-I1 can be found here.
Brochure containing facts and figures and other information about the MTG system can be found here.
The full Meteosat Third Generation constellation will comprise two imaging satellites and, for the first time, a sounding satellite. MTG – Sounder 1, is expected to be launched in 2024.
MTG-I1 was built by Thales Alenia Space under contract by the European Space Agency (ESA). ESA is responsible for procuring the satellites from industry fulfilling EUMETSAT’s requirements.
Thales Alenia Space Cannes is the prime industrial partner for the development of the MTG-I satellites. TAS works in close cooperation with:
• OHB-Bremen, which assembled, integrated and tested the platform
• LEONARDO in Italy, which provided the Lightning Imager instrument
• Thales Alenia Space Italy, which delivered the Data Collection and GEO SAR instruments
• Thales Alenia Space Cannes also integrated the Flexible Combined Imager.
For more information, visit the EUMETSAT website.
About EUMETSAT
EUMETSAT, Europe’s meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies.
Three Meteosat Second Generation satellites in geostationary orbit deliver continuous observations of fast developing severe weather events over Europe, Africa and the Indian Ocean. The first of the Meteosat Third Generation satellites was launched in December 2022 and will undergo 12 months’ in-orbit commissioning. Two polar-orbiting Metop satellites provide data of pivotal importance for forecasts up to 10 days ahead. The first of the second-generation Metop satellites is expected to be launched in 2025.
EUMETSAT’s archive of satellite observations over more than 40 years provides climate scientists around the world with long-term, homogenous data necessary for monitoring climate change.
EUMETSAT is a key partner in the European Union’s Copernicus Earth observation programme. It operates the Copernicus Sentinel-3 and -6 ocean-monitoring missions, and will operate the upcoming CO2M mission, to monitor carbon dioxide emissions. EUMETSAT will fly the Copernicus Sentinel-4 and -5 missions on board its own MTG and Metop-SG satellites. Data from these Sentinels, and EUMETSAT’s own missions, are provided to the Copernicus climate, atmosphere monitoring and marine environment services. Along with European Space Agency and the European Centre for Medium-Range Weather Forecasts, EUMETSAT is a partner in the EU’s DestinE initiative, creating digital twins of the entire Earth system.
Together with NASA, NOAA, the EU, ESA and with support from the French Space Agency, CNES, EUMETSAT is a partner in the Jason and Copernicus Sentinel-6 ocean-monitoring missions.
EUMETSAT cooperates with agencies around the world, securing additional satellite data of benefit to weather forecasting and climate monitoring.
EUMETSAT’s 30 member states are: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005463/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
